Susquehanna International Group
SLN

Susquehanna International Group’s Silence Therapeutics SLN Stock Holding History

Susquehanna International Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
20,200
-4,800
-19% -$26.4K ﹤0.01% 12302
2025
Q4 		$152K Buy
+25,000
New +$160K ﹤0.01% 11155

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Susquehanna International Group's SLN Position: Q1 2026 in Review

Susquehanna International Group increased its Silence Therapeutics (SLN) stake by 584% in Q1 2026, buying an estimated $542K and bringing the position to 115,281 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #9160.

Susquehanna International Group first reported a position in SLN in Q2 2025 and has held it in 3 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Susquehanna International Group held 115,281 shares of Silence Therapeutics worth $608K as of Q1 2026.
  • Susquehanna International Group bought 98,415 Silence Therapeutics shares in Q1 2026, an estimated $542K.
  • Silence Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9160 holding.
  • Susquehanna International Group first reported a position in Silence Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.